Last updated on February 2018

Study of Adjuvant ONO-4538 With Resected Gastric Cancer


Brief description of study

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Clinical Study Identifier: NCT03006705

Contact Investigators or Research Sites near you

Start Over

Ono Pharmaceutical Co. Ltd Corporate ...

Kanagawa Clinical Site
Yokohama, Japan
  Connect »